Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Susser, Simone ^a   Herrmann, Eva ^a   Lange, Christian ^a   Hamdi, Nabila ^b   Müller, Tobias ^c   Berg, Thomas ^c   Perner, Dany ^a   Zeuzem, Stefan ^a   Sarrazin, Christoph ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b German University in Cairo   (Egypt)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; BOCEPREVIR; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; IFNL4 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; RECOMBINANT PROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; EGYPT; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GERMANY; HEPATITIS C; HUMAN; IFN L4 GENE; IL28B GENE; MAJOR CLINICAL STUDY; MEASUREMENT ACCURACY; PREDICTIVE VALUE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG MONITORING; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST PATHOGEN INTERACTION; METABOLISM; PHYSIOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; VIROLOGY;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; DRUG MONITORING; GENE EXPRESSION REGULATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84911948122     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112592     Document Type: Article

References (38)

1. WHO (2013) World Health Organization. Hepatitis C. Fact Sheet No.164. Available: Http://www.who.int/mediacentre/factsheets/fs164/en/index.html.
2. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56 Suppl 1: S88-100. S0168-8278(12)60010-5 [pii];10.1016/S0168-8278(12)60010-5 [doi].
3. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, et al. (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368: 1867-1877. 10.1056/NEJMoa1214854 [doi].
4. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, et al. (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370: 211-221. 10.1056/NEJMoa1306218 [doi].
5. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, et al. (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368: 1878-1887. 10.1056/NEJMoa1214853 [doi].
6. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, et al. (2013) Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368: 34-44. 10.1056/NEJMoa1208953 [doi].
7. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, et al. (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364: 1207-1217. 10.1056/NEJMoa1009482 [doi].
8. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, et al. (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364: 2417-2428. 10.1056/NEJMoa1013086 [doi].
9. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416. 10.1056/NEJMoa1012912 [doi].
10. Poordad F, McCone J Jr., Bacon BR, Bruno S, Manns MP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206. 10.1056/NEJMoa1010494 [doi].
11. Pearlman BL, Ehleben C (2014) Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology 59: 71-77. 10.1002/hep.26624 [doi].
12. Nelson DR, Poordad F, Feld JJ, Fried MW, Jacobson IM, et al. (2013) High SVR Rates (SVR4) for 12-Week Total Telaprevir Combination Therapy in Il28B CC Treatment-Naives and Prior Relapsers with G1 Chronic Hepatitis C: CONCISE Interim Analysis. J Hepatol 58: S362.
13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401. nature08309 [pii];10.1038/nature08309 [doi].
14. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-Alpha and ribavirin therapy. Nat Genet 41: 1100-1104. ng.447 [pii];10.1038/ng.447 [doi].
15. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-Alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109. ng.449 [pii];10.1038/ng.449 [doi].
16. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, et al. (2011) Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 54: 415-421. S0168-8278(10)00834-2 [pii];10.1016/j.jhep.2010.07.041 [doi].
17. Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Garcia-Alvarez M, Resino S (2013) Meta-Analysis: Implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med 11: 6. 1741-7015-11-6 [pii];10.1186/1741-7015-11-6 [doi].
18. Schreiber J, Moreno C, Garcia BG, Louvet A, Trepo E, et al. (2012) Metaanalysis: The impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. Aliment Pharmacol Ther 36: 353-362. 10.1111/j.1365-2036.2012.05197.x [doi].
19. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, et al. (2012) Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 143: 608-618. S0016-5085(12)00739-1 [pii];10.1053/j.gastro.2012.05.011 [doi].
20. Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz EJ, et al. (2013) Limited impact of IL28B genotype on response rates in telaprevir-Treated patients with prior treatment failure. J Hepatol 58: 883-889. S0168-8278(13)00010-X [pii];10.1016/j.jhep.2012.12.023 [doi].
21. Fischer J, Bohm S, Scholz M, Muller T, Witt H, et al. (2012) Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 55: 1700-1710. 10.1002/hep.25582 [doi].
22. Rauch A, Kutalik Z, Descombes P, Cai T, Di IJ, et al. (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genomewide association study. Gastroenterology 138: 1338-45, 1345. S0016-5085(10)00008-9 [pii];10.1053/j.gastro.2009.12.056 [doi].
23. Mangia A, Mottola L, Santoro R (2013) Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. World J Gastroenterol 19: 8924-8928. 10.3748/wjg.v19.i47.8924 [doi].
24. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, et al. (2013) IL28B expression depends on a novel TT/2G polymorphism which improves HCV clearance prediction. J Exp Med 210: 1109-1116. jem.20130012 [pii];10.1084/jem.20130012 [doi].
25. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, et al. (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45: 164-171. ng.2521 [pii];10.1038/ng.2521 [doi].
26. Sarrazin C, Schwendy S, Moller B, Dikopoulos N, Buggisch P, et al. (2011) Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology 141: 1656-1664. S0016-5085(11)00983-8 [pii];10.1053/j.gastro.2011.07.019 [doi].
27. Shemis MA, El-Abd DM, Ramadan DI, El-Sayed MI, Guirgis BS, et al. (2012) Evaluation of multiplex nested polymerase chain reaction for routine hepatitis C virus genotyping in egyptian patients. Hepat Mon 12: 265-270. 10.5812/hepatmon.830 [doi].
28. Hothorn T, Hornik K, Zeileis A (2006) Unbiased recursive partitioning: A conditional inference framework. Journal of Computational and Graphical Statistics 15: 651-674.
29. Lagging M (2012) Impact of IL28B SNPs on therapeutic outcome and liver histology differs between hepatitis C virus genotypes. Pharmacogenomics 13: 847-849. 10.2217/pgs.12.57 [doi].
30. Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, et al. (2014) IFNL4-DeltaG Genotype Is Associated With Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated With Sofosbuvir and Ribavirin. J Infect Dis 209: 1700-1704. jit827 [pii];10.1093/infdis/jit827 [doi].
31. Metz P, Reuter A, Bender S, Bartenschlager R (2013) Interferon-stimulated genes and their role in controlling hepatitis C virus. J Hepatol 59: 1331-1341. S0168-8278(13)00548-5 [pii];10.1016/j.jhep.2013.07.033 [doi].
32. Heim MH (2013) Innate immunity and HCV. J Hepatol 58: 564-574. S0168-8278(12)00772-6 [pii];10.1016/j.jhep.2012.10.005 [doi].
33. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105: 7034-7039. 0707882105 [pii];10.1073/pnas.0707882105 [doi].
34. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, et al. (2010) Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139: 499-509. S0016-5085(10)00657-8 [pii];10.1053/j.gastro.2010.04.049 [doi].
35. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52: 1888-1896. 10.1002/hep.23912 [doi].
36. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, et al. (2011) Interferoninduced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140: 1021-1031. S0016-5085(10)01729-4 [pii];10.1053/j.gastro.2010.11.039 [doi].
37. Duong FH, Trincucci G, Boldanova T, Calabrese D, Campana B, et al. (2014) IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFNalpha therapies. J Exp Med 211: 857-868. jem.20131557 [pii];10.1084/jem.20131557 [doi].
38. Stättermayer AF, Strassl R, Maieron A, Rutter K, Stauber R, et al. (2014) Polymorphisms of interferon-lambda4 and IL28B -effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther 39: 104-111. 10.1111/apt.12547 [doi].